Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/6/2019 |
Start Date: | June 1, 2016 |
End Date: | August 17, 2021 |
Contact: | Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: |
Email: | JNJ.CT@sylogent.com |
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML
The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and
identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and
to characterize the safety and tolerability of JNJ-63709178 at the RP2D(s) in Part 2.
identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and
to characterize the safety and tolerability of JNJ-63709178 at the RP2D(s) in Part 2.
This is first-in-human (FIH) Phase 1, open-label (identity of assigned study drug will be
known), multicenter, dose escalation study with dose expansion to identify the RP2D and to
evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-63709178 in
adult participants with relapsed or refractory acute myeloid leukemia (AML) who are
ineligible for or have exhausted standard therapeutic options. The study is divided into 3
periods: a Screening Phase (within 28 days before the first dose of study drug), a Treatment
Phase (first dose of study drug until the last dose of study drug) and a Post-treatment
Follow-up Phase (up to the end of study participation or end of study). Participants' safety
will be monitored throughout the study.
known), multicenter, dose escalation study with dose expansion to identify the RP2D and to
evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-63709178 in
adult participants with relapsed or refractory acute myeloid leukemia (AML) who are
ineligible for or have exhausted standard therapeutic options. The study is divided into 3
periods: a Screening Phase (within 28 days before the first dose of study drug), a Treatment
Phase (first dose of study drug until the last dose of study drug) and a Post-treatment
Follow-up Phase (up to the end of study participation or end of study). Participants' safety
will be monitored throughout the study.
Inclusion Criteria:
- A diagnosis of acute myeloid leukemia (AML) according to the World Health Organization
2008 criteria with relapsed or refractory disease and ineligible for or have exhausted
standard therapeutic options
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Hematology laboratory parameters within the Protocol specified range
- Chemistry laboratory parameters within the Protocol specified range
- A woman of childbearing potential must have a negative highly sensitive serum (beta
human chorionic gonadotropin [b-hCG]) or urine test prior to the first dose of study
drug
Exclusion Criteria:
- Acute promyelocytic leukemia
- Active central nervous system involvement
- Prior solid organ transplantation
- Prior hematopoietic stem cell transplant within 6 months of enrollment. If the
participant had an allogenic transplant there must be no apparent signs of graft
versus host disease and participants must have discontinued all immunosuppressive
therapies for at least 4 weeks
- Prior treatment with a CD123xCD3 bispecific agent, T cells expressing CD123 specific
chimeric antigen receptor, or toxin-conjugated to CD123 antibodies; prior treatment
with naked anti-CD123 monoclonal antibody is permitted
We found this trial at
15
sites
Click here to add this to my saved trials
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
Click here to add this to my saved trials
1021 Morehead Medical Drive
Charlotte, North Carolina 28204
Charlotte, North Carolina 28204
Click here to add this to my saved trials
Click here to add this to my saved trials
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials